Acme United (ACU) Q1 2023: First Aid Share Climbs to 59%, Margin Gains Offset Debt Cost Surge
Acme United’s Q1 highlighted the company’s pivot toward first aid products, now 59% of sales, and a sharp operating margin rebound despite a tripling of interest expense. Inventory and cost discipline drove improved cash flow and profitability, even as customer inventory reductions and macro headwinds persisted. Management signals further operational gains, ongoing portfolio reshaping, and selective M&A as key levers for 2023.
Summary
- First Aid Expansion: First aid and medical now dominate the portfolio, reshaping Acme’s growth profile.
- Operational Leverage: Margin recovery and SG&A control outpaced inflation and rate-driven cost spikes.
- Debt and Cash Focus: Inventory reduction and disciplined capital allocation underpin a cautious but constructive outlook.
Business Overview
Acme United is a supplier of cutting, measuring, and safety products, with a growing focus on first aid and medical supplies. The company generates revenue through branded product sales to retail, industrial, and medical channels across the U.S., Canada, and Europe. Its core segments include first aid (kits, refills, medical accessories), Westcott (scissors, rulers), and Clauss (cutting tools), with first aid now comprising the majority of sales.
Performance Analysis
Acme United delivered a 6% year-over-year sales increase in Q1 2023, led by U.S. segment strength in first aid and medical products. The U.S. segment’s 9% sales growth offset modest declines in Europe and Canada, where customer inventory reductions weighed on demand. Gross margin rose to 35.5%, up from 34.5% a year ago, reflecting productivity initiatives and easing supply chain costs.
SG&A expenses fell as a percentage of sales, amplifying operating leverage and driving a 60% jump in operating profit. However, interest expense nearly tripled due to sharply higher rates on variable debt, partially muting net income gains. Acme reduced net debt by $6.5 million through disciplined inventory management and limited capex, supporting improved free cash flow and balance sheet flexibility.
- First Aid Mix Shift: First aid and medical products now comprise 59% of total sales, up from 55% last year, anchoring Acme’s business model in higher-margin, recurring categories.
- Cost Structure Reset: Productivity gains and lower abnormal shipping costs supported margin expansion, while SG&A discipline further improved profitability.
- Interest Rate Drag: A 6.4% average interest rate in Q1, versus 2.4% last year, drove a $600,000 increase in interest expense, highlighting sensitivity to rate cycles.
Customer inventory normalization remains a headwind, but management expects this to abate by Q3, positioning Acme for a stronger second half.
Executive Commentary
"Net sales increased despite ongoing reductions in inventory by our customers. Our gross margins benefited from productivity improvement. The expense reductions in SG&A that we began in 2022 are becoming evident. With sales up, gross margins up, and SG&A down, our operating income increased 60% in the first quarter."
Walter C. Johnson, Chairman and CEO
"Net sales in the U.S. segment increased 9% in the quarter mainly due to higher sales of first aid and medical products. The gross margin was 35.5% in the first quarter of 2023 versus 34.5%... mainly due to the productivity improvement initiatives that began in Q4 of 2022."
Paul Driscoll, Chief Financial Officer
Strategic Positioning
1. First Aid and Medical as Core Growth Engine
First aid and medical now represent the majority of Acme’s revenue, up to 59% from 55% last year, signaling a deliberate portfolio shift toward higher-margin, less cyclical categories. Management emphasized vertical integration opportunities, such as the MedNav acquisition, to deepen control over kit components and enhance recurring revenue potential.
2. Operational Productivity and Inventory Discipline
Warehouse automation and process improvements at the Rocky Mountain, NC facility, combined with workforce stability initiatives, are driving sustained productivity gains. Inventory was reduced by $5 million in Q1, with further reductions targeted, supporting both working capital efficiency and debt paydown.
3. Margin Expansion and Cost Containment
SG&A as a percentage of sales declined, reflecting ongoing cost containment efforts begun in 2022. The normalization of container shipping costs and the winding down of abnormal supply chain expenses further underpin gross margin recovery.
4. Selective M&A and Portfolio Optimization
Management remains active in evaluating acquisition opportunities, with a focus on either expanding first aid vertical integration or consolidating within core product categories. The SafetyMate and MedNav deals illustrate a preference for synergistic, accretive targets that reinforce Acme’s evolving business mix.
5. Debt and Rate Risk Management
With variable debt at $41 million and rising interest costs, Acme is prioritizing debt reduction through inventory and capex discipline. The company’s fixed-rate mortgages provide some cost stability, but further rate hikes remain a material risk.
Key Considerations
Acme’s Q1 results reflect a business in transition, leveraging operational discipline and portfolio mix shifts to counterbalance macro and financial headwinds.
Key Considerations:
- First Aid Penetration: The continued growth of first aid as a share of sales increases recurring revenue stability but also raises exposure to expiration-driven inventory management challenges.
- Customer Inventory Cycles: Ongoing destocking by key retail and online channels could persist into Q3, delaying full revenue normalization.
- Interest Rate Exposure: Variable rate debt amplifies sensitivity to further Fed tightening, directly impacting net income and cash flow.
- Productivity Levers: Warehouse automation and workforce retention are delivering margin gains, but sustaining these improvements will be critical as supply chain normalization continues.
Risks
Acme faces ongoing risks from further interest rate increases, which could drive up debt service costs and compress earnings. Customer inventory reductions, particularly in retail and online channels, may extend longer than anticipated, delaying revenue recovery. Additionally, macroeconomic uncertainty and potential supply chain disruptions remain live threats, as highlighted by management’s caution around global financial system stress and the lack of formal guidance for 2023.
Forward Outlook
For Q2 2023, Acme United did not provide explicit quantitative guidance but signaled:
- Expectation of continued operational improvement and further inventory reduction.
- Anticipation that customer inventory normalization will largely conclude by Q3, supporting stronger second-half performance.
For full-year 2023, management withheld formal guidance but expressed confidence in delivering improved results versus 2022, underpinned by ongoing cost control, debt reduction, and selective M&A activity.
- Management expects margin gains and cash flow to offset some interest rate headwinds.
- Acquisition pipeline remains active, with a likely transaction possible in the back half of the year.
Takeaways
Acme United’s Q1 demonstrates the company’s ability to offset macro and rate headwinds through margin expansion, operational discipline, and a decisive shift toward first aid and medical products.
- Margin and Mix: Margin recovery and first aid mix gains are mitigating external pressures, with further upside if customer inventories stabilize as expected.
- Debt and Cash Prioritization: Inventory reduction and capex restraint are supporting balance sheet resilience in a rising rate environment.
- Strategic Optionality: Ongoing M&A and vertical integration initiatives will be critical to sustaining growth and diversifying risk in a volatile macro backdrop.
Conclusion
Acme United’s Q1 2023 results highlight a business leaning into operational discipline and portfolio realignment to drive resilience and margin gains. Investors should watch for continued first aid expansion, debt reduction progress, and the timing of customer inventory normalization as key drivers of second-half performance.
Industry Read-Through
Acme’s experience underscores broader themes in the industrial and consumer product sectors: Inventory normalization remains a drag on near-term sales, but operational productivity and cost control can offset macro headwinds. Rising interest costs are a material concern for companies with variable debt, incentivizing accelerated working capital efficiency and capex discipline. The pivot toward medical and first aid products reflects a wider industry trend of seeking stable, recurring revenue streams in uncertain environments. Peers with similar exposure to retail inventory cycles or floating rate debt should heed Acme’s focus on operational agility and portfolio mix shifts as defensive levers.